Antares Pharma Says It Doesn't Need To Conduct Any New Clinical Studies To Support A Re-Submission Of XYOSTED's New Drug Application, Anticipates Resubmission Will Include Re-Analysis Of Existing Data, Address Labeling And Post-Approval Risk Mitigation